25:30 Sunday Quiz 29:00 Weekly case : Secondary triple positive APS 33:00 Thrombocytosis in SLE 34:30 Autosplenectomy 38:00 Challenges in setting up a BMT unit in LMIC 41:12 APBMT 22 countries 42:10 Minimal standards 51:30 National Guidelines for HCT (ICMR) 55:35 Book chapter by Dr Joseph John and Dr Mammen Chandy 56:25 Physical Design 1:01:40 HVAC 1:06:40 Cure2Children Approach 1:07:48 Basic Equipment 1:08:10 List of essential drugs for pediatric BMT and lab tests
17:00 Age vs survival 20:05 ALCL 23:05 Nodal TFH 24:20 PTCL 25:05 ENTNKcL 30:05 Histopathology 33:30 Alk negative ALCL - Donut cells, less EMA, no cytotoxic pattern 35:50 PTCL, NOS histopath 37:55 Alk neg ALCL vs PTCL 38:35 AITL 40:15 TFH lymphomas 45:25 Prognostic scoring 47:38 Treatment: CHOP vs Gem vs Bevacizumab vs Alemtuzumab 49:33 Addition of Etoposide - less than 60 yrs, normal LDH, Alk positive, (nodal PTCL) 50: 40 DA EPOCH 50:55 Echelon 2 52:35 Addition of oral azacitidine to CHOP 54:00 RoCHOP 54: 30 Role of Transplant 57:30 Role of Radiation 58:20 Newer agents 59:16 NKTCL - Chinese SWOG/ALSG staging 1:00:12 Prognostic scoring system - IPI, KPI, PINK, NRI 1:00:37 Treatment of NKTCL
Sir I am from Lahore. Excellent and extremely useful presentation. Please have more such useful presentations, so that I can benefit more from u. dr Fareed.
How would I reach this professor by email?
Dr. Swerdlow said he had previously a talk on DLBCL in this platform ? but I could not find it. Anyone has the link ? Thanks !
Very nice presentation ❤
1:16:10 Quiz Answer 1:22:00 Discussion
25:30 Sunday Quiz 29:00 Weekly case : Secondary triple positive APS 33:00 Thrombocytosis in SLE 34:30 Autosplenectomy 38:00 Challenges in setting up a BMT unit in LMIC 41:12 APBMT 22 countries 42:10 Minimal standards 51:30 National Guidelines for HCT (ICMR) 55:35 Book chapter by Dr Joseph John and Dr Mammen Chandy 56:25 Physical Design 1:01:40 HVAC 1:06:40 Cure2Children Approach 1:07:48 Basic Equipment 1:08:10 List of essential drugs for pediatric BMT and lab tests
17:00 Age vs survival 20:05 ALCL 23:05 Nodal TFH 24:20 PTCL 25:05 ENTNKcL 30:05 Histopathology 33:30 Alk negative ALCL - Donut cells, less EMA, no cytotoxic pattern 35:50 PTCL, NOS histopath 37:55 Alk neg ALCL vs PTCL 38:35 AITL 40:15 TFH lymphomas 45:25 Prognostic scoring 47:38 Treatment: CHOP vs Gem vs Bevacizumab vs Alemtuzumab 49:33 Addition of Etoposide - less than 60 yrs, normal LDH, Alk positive, (nodal PTCL) 50: 40 DA EPOCH 50:55 Echelon 2 52:35 Addition of oral azacitidine to CHOP 54:00 RoCHOP 54: 30 Role of Transplant 57:30 Role of Radiation 58:20 Newer agents 59:16 NKTCL - Chinese SWOG/ALSG staging 1:00:12 Prognostic scoring system - IPI, KPI, PINK, NRI 1:00:37 Treatment of NKTCL
46:15 Therapeutic targets in myeloma 47:24 Agents approved for treatment of Myeloma April 2023 48:42 Determination Trial 54:00 Forte Trial 58:20 UK OPTIMUM/MUKnine 1:00:30 SKY92 1:03:25 GMMG concept Trial 1:03:50 Response adapted therapy 1:05:00 EMN02/HOVON95, Myeloma IX 1:06:50 Lenalidomide maintenance 1:07:02 Future directions : KARMMA - 3; CARTITUDE - 1 1:12:00 MajesTEC1 1:16:45 Sankey plot lines of therapy 1:17:45 Thank you (GK 🙂) 1:19:00 Q and A
MONALI MAM GOOD TO HEAR FROM YOU
Sir I am from Lahore. Excellent and extremely useful presentation. Please have more such useful presentations, so that I can benefit more from u. dr Fareed.
excellent presentation
Excellent class
beautifully explained sir
Who understand her language?
EXCELLENT PRESENTATION ...VERY INFORMATIVE ...THANKS SIR
Can you please upload last saturday webinar?
Please more information 🙏🏻
Gud Academic Sir....
Gud Academic Sir...
Starts at -1:29
Excellent lecture ,, I would like more such teaching sessions from you . Very informative lecture .